Alnylam Pharmaceuticals - FDA Approval Expansion for Amvuttra Significantly Boosts Earnings!
Reading Time: 1 minute
Business Driver: Alnylam Pharmaceuticals (ALNY) is one of the world's leading providers of so-called RNAi therapeutics, which open up new promising treatment approaches for genetic diseases, cardio-metabolic diseases, infectious diseases, as well as central nervous system (CNS) disorders. With Oxluma (treatment of adults with Primary Hyperoxaluria Type 1 (PH1)), Givlaari (treatment of acute hepatic porphyria (AHP)), Onpaatro (ATTR amyloidosis), and Amvuttra (treatment of rare forms of transthyretin amyloidosis in adult patients with cardiomyopathy),...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
